Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

about

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.

P2860

Q55045610-4B1A3B0A-44B0-4A83-BD1C-A21CD3906A96

P2860

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Item

http://www.wikidata.org/entity/Q38866636

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alemtuzumab consolidation in c ...... phase I/II multicentre trial.

@en

type

Item

label

Alemtuzumab consolidation in c ...... phase I/II multicentre trial.

@en

prefLabel

Alemtuzumab consolidation in c ...... phase I/II multicentre trial.

@en

P1476

Alemtuzumab consolidation in c ...... phase I/II multicentre trial.

@en

P2093

Barbara F Eichhorst

http://www.w3.org/2001/XMLSchema#string

Carmen D Herling

http://www.w3.org/2001/XMLSchema#string

Jasmin Bahlo

http://www.w3.org/2001/XMLSchema#string

Kirsten Fischer

http://www.w3.org/2001/XMLSchema#string

Matthias Ritgen

http://www.w3.org/2001/XMLSchema#string

Michael Kneba

http://www.w3.org/2001/XMLSchema#string

Raymonde Busch

http://www.w3.org/2001/XMLSchema#string

Sebastian Böttcher

http://www.w3.org/2001/XMLSchema#string

Thomas Elter

http://www.w3.org/2001/XMLSchema#string

Ute Elberskirch

http://www.w3.org/2001/XMLSchema#string

P2860

Perturbation of the normal immune system in patients with CLL

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

Pharmacokinetics of alemtuzumab and the relevance in clinical practice.

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.

P304

254-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12825

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hallek

Clemens-Martin Wendtner

Othman Al-Sawaf

Stephan Stilgenbauer

P577

2016-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27862308

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

phase I clinical trial

phase II clinical trial

multicenter trial

lymphocyte

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

about

P2860

P2860

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921